Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription

Blood

Volumn 90, Issue 3, 1997, Pages 1141-1149

  McNeely, Tessie B ^a   Shugars, Diane C ^b   Rosendahl, Mary ^b   Tucker, Christina ^b   Eisenberg, Stephen P ^b   Wahl, Sharon M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS TRANSCRIPTION; VIRUS VIRULENCE;

EID: 0030741731     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.3.1141     Document Type: Article

References (43)

1. Freidland GH, Saltzman BR, Rogers MF, Kahl PA, Lesser ML, Meyers MM, Klein RS: Lack of household transmission of HTLV-III infection. N Engl J Med 314:344, 1986
2. Moore BE, Flaitz CM, Coppenhaver DH, Nichols CM, Kalmaz GD, Bessman JD, Cloyd MW, Lynch DP, Prabhakar BS, Baron S: HIV recovery from saliva before and after dental treatment: Inhibitors may have critical role in viral inactivation. J Am Dent Assoc 124:67, 1993
3. Klein RS, Phelan JA, Freeman PH, Schable MS, Friedland GH, Trieger N, Steigbigel NH: Low occupational risk of human immunodeficiency virus infection among dental professionals. N Engl J Med 318:86, 1988
4. Fultz PN: Components of saliva inactivate human immunodeficiency virus. Lancet 2:1215, 1986
5. Fox PC, Wolff A, Yeh C-K, Atkinson JC, Baum BJ: Saliva inhibits HIV-1 infectivity. J Am Dent Assoc 116:635, 1988
6. Archibald DW, Cole GA: In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res Hum Retroviruses 6:1425, 1990
7. Coppenhaver DH, Sriyuktasuth-Woo P, Baron S, Barr CE, Qureshi MN: Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. N Engl J Med 330:1314, 1994
8. Robinovitch MR, Iversen JM, Resnick L: Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus. Crit Rev Oral Biol Med 4:455, 1993
9. Malamud D, Davis C, Berthold P, Roth E, Friedman H: Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses 9:633, 1993
10. Bergey EJ, Cho M-I, Hammarskjold M-L, Rekosh D, Levine MJ, Blumberg BM, Epstein LG: Aggregation of human immunodeficiency virus type 1 by human salivary secretions. Crit Rev Oral Biol Med 4:467, 1993
11. McNeely TM, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96:456, 1995
12. Wahl SM, McNeely TB, Janoff EN, Shugars DC, Worley P, Tucker C, Orenstein JM: Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis (in press)
13. Wahl SM, Worley P, Jin WW, McNeely TB, Eisenberg S, Orenstein JM, Janoff E: Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissue. Am J Pathol 150:1275, 1997
14. Shugars DC, Pauls DL, Weinberg JB: Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis (in press)
15. Kramps JA, Franken C, Dijkman JG: ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum. Am Rev Respir Dis 129:959, 1984
16. + cells. Science 262:2045, 1993
17. Moore JP, Nara PL: The role of the V3 loop of gp120 in HIV infection. AIDS 5:S21, 1991 (suppl 2)
18. Clements GJ, Price-Jones MJ, Stephens PE, Sutton C, Schulz TF, Clapham PR, McKeating JA, McClure MO, Thomson MO, Marsh M, Kay J, Weiss RA, Moore JP: The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: A possible function in viral fusion? AIDS Res Hum Retroviruses 7:3, 1991
19. Hattori T, Koito A, Takatsuki K, Kido H, Katunuma N: Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection. FEBS Lett 248:48, 1989
20. Bristow CL, Fiscus SA, Flood PM, Arnold RR: Inhibition of HIV-1 by modification of a host membrane protease. Int Immunol 7:239, 1995
21. + T cells. Science 270:1811, 1996
22. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955, 1996
23. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661, 1996
24. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667, 1996
25. Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 83:6692, 1986
26. Wahl SM, Orenstein JM, Smith PD: Macrophage function in HIV infection, in Gupta S (ed): Immunology of HIV Infection. New York, NY, Plenum, 1996, p 303
27. Mottet HSLM, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai Q-H, Sharer LR, McComb RD, Swindells S, Soderland C, Gendelman HE: Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 156:1284, 1996
28. Wahl LM, Katona IM, Wilder RL, Winter CC, Haraoui B, Scher I, Wahl SM: Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation. I. Characterization of B lymphocyte, T lymphocyte and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol 85:373, 1984
29. Eisenberg SP, Hale KK, Heimdal P, Thompson RC: Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 265:7976, 1990
30. Vogelmeier C, Hubbard RC, Fells GA, Schnebli H-P, Thompson RC, Fritz H, Crystal RG: Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 87:482, 1991
31. Stolk J, Heinzel-Wieland R, Saunders D, Dijkman JH, Steffens G: Potency of an oxidation-resistant mutant of secretory leukocyte proteinase inhibitor in lipopolysaccharide-induced emphysema in hamsters. Pulm Pharmacol 6:3, 1993
32. Carp H, Janoff A: Inactivation of bronchial mucous proteinase inhibitor by cigarette smoke and phagocyte-derived oxidants. Exp Lung Res 1:225, 1980
33. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M: The role of mononuclear phagocytes in HTLV-III/ LAV infection. Science 233:215, 1986
34. Finberg RW, Wahl SM, Allen JB, Soman G, Strom TB, Murphy JR, Nichols JC: Selective elimination of HIV-1 -infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252:1703, 1991
35. Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, Valente AJ, Baker JB: Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest 88:1362, 1991
36. Rice WG, Schaeffer CA, Graham L, Bu M, McDougal JS, Orloff SL, Villinger F, Young M, Oroszlan S, Fesen MR, Pommier Y, Mendeleyev J, Kun E: The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc Natl Acad Sci USA 90:9721, 1993
37. Cann AJ, Zack JA, Go AS, Arrigo SJ, Koyanagi Y, Green PL, Koyanagi Y, Pang S, Chen ISY: Human immunodeficiency virus type 1 t-cell tropism is determined by events prior to provirus formation. J Virol 64:4735, 1990
38. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91:9770, 1994
39. Campbell EJ, Silverman EK, Campbell MA: Elastase and cathepsin G of human monocytes. J Immunol 143:2961, 1989
40. Avril L-E, Martino-Ferrer MC, Pignede G, Seman M, Gauthier F: Identification of the U-937 membrane-associated proteinase interacting with the V3 loop of HTV-1 gp120 as cathepsin G. FEBS Lett 345:81, 1994
41. Avril L-E, di Martino-Ferrer M, Brillard-Bourdet M, Gauthier F: Inhibition of U-937 membrane-associated cathepsin G by GP120(IIIB) and V3 loop-derived peptides from several strains of HIV-1, FEBS Lett 367:251, 1995
42. Grutter GM, Fendrich G, Huber R, Bode W: The 2.5 x-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine a-chymotrypsin. EMBO J 7:345, 1988
43. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk H-D, Garten W: Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358, 1992